Specifically, knocking down this receptor by about 50% in a human tauopathy neuron-like cellular model reduced the acute (24-h treatment) but not the long-term (5-day treatment) efficacy of the highly effective tau antibodies 5G2 and 4E6 in clearing tau by a similar percentage. Here, MAPT is linked to tauopathy.